• FGF Signaling Drives Non-Cell Autonomous Apoptosis Resistanc

  2026-07-22

  The referenced study uncovers a novel mechanism whereby apoptotic stress triggers fibroblast growth factor (FGF) signaling, leading to non-cell autonomous resistance to apoptosis through upregulation of pro-survival BCL-2 proteins. These findings have significant implications for understanding drug resistance in cancer therapy and the interplay between tissue damage, survival, and repair.

• NF-κB/miR-202-5p/HMGB2 Loop Attenuates Septic Kidney Injury

  2026-07-22

  This study reveals a protective negative feedback loop involving NF-κB, miR-202-5p, and HMGB2 that attenuates inflammation and cell death in sepsis-induced acute kidney injury (AKI). These findings clarify a key adaptive mechanism in renal tubular cells and suggest new molecular targets for inflammation-focused AKI research.

• PBS (Phosphate-Buffered Saline): Technical Parameters & Work

  2026-07-21

  PBS (Phosphate-Buffered Saline) offers a sterile, isotonic buffer with physiological pH, supporting cell washing, substance dilution, and protein assay workflows in laboratory research. It is not suitable for diagnostic, clinical, or in vivo use, and should be reserved for controlled in vitro applications.

• PX-478 2HCl: Redefining Hypoxia Pathway Research in Cancer a

  2026-07-21

  PX-478 2HCl, a potent HIF-1α inhibitor from APExBIO, is catalyzing a paradigm shift in hypoxia signaling research—bridging mechanistic oncology, neurodevelopmental disease, and translational protocol innovation. This article provides actionable insight into the molecule’s dual impact on radiosensitization and neuroprotection, underpinned by recent evidence in cancer and autism spectrum disorder (ASD) models. We highlight protocol best practices, emerging mechanistic understanding, and the strategic implications for translational researchers seeking to harness hypoxia biology across domains.

• TBK1 Inhibition Reduces Microglia Pyroptosis in Diabetic Neu

  2026-07-20

  Liao et al. (2024) reveal that TANK-binding kinase 1 (TBK1) activation in spinal microglia drives painful diabetic neuropathy (PDN) via pyroptosis, and that TBK1 inhibition alleviates this process. These findings identify TBK1 as a mechanistic link between neuroinflammation and PDN, suggesting new therapeutic strategies for diabetic complications.

• Bufuralol Hydrochloride: Advancing Human-Relevant β-Adrenerg

  2026-07-20

  This thought-leadership article explores how bufuralol hydrochloride, a non-selective β-adrenergic receptor antagonist with partial intrinsic sympathomimetic activity, is transforming cardiovascular pharmacology workflows. By bridging mechanistic insight with strategic guidance, we highlight the integration of bufuralol in next-generation hiPSC-derived intestinal organoid models and address key challenges in translational β-adrenergic modulation studies. Evidence from recent organoid research and competitive landscape analyses contextualize bufuralol’s unique value for translational scientists seeking human-relevant, reproducible, and predictive outcomes.

• Vitamin C and NAC Inhibit ROS/NF-κB Pathway in Cochlear Sene

  2026-07-19

  A recent study demonstrates that vitamin C and N-acetylcysteine (NAC) both ameliorate D-galactose-induced senescence in cochlear hair cells by inhibiting the ROS/NF-κB pathway. This finding clarifies the mechanistic basis of antioxidant interventions in age-related hearing loss and provides a validated in vitro model for further research on oxidative stress pathway modulation.

• Standardized Whole-Blood Stimulation Reveals Metabolic Immun

  2026-07-18

  This study introduces a reproducible protocol for analyzing immune responses by combining whole-blood stimulation with precise metabolic modulation. The findings clarify how distinct metabolic inhibitors, including dehydrogenase inhibitors, selectively shape cytokine production, enabling more robust immunometabolism research.

• Monomethyl auristatin E: Optimizing ADC Payloads in Cancer T

  2026-07-17

  Monomethyl auristatin E (MMAE) empowers antibody-drug conjugate (ADC) workflows with sub-nanomolar potency, precise targeting, and robust selectivity across challenging cancer models. This guide details actionable protocols, advanced troubleshooting, and insights from recent studies—positioning APExBIO’s MMAE as a transformative tool for translational oncology.

• Gasdermin C Drives Stemness and Immune Evasion in PDAC

  2026-07-17

  This study reveals a pyroptosis-independent role for Gasdermin C (GSDMC) in promoting cancer stemness and immune evasion in pancreatic ductal adenocarcinoma (PDAC). By uncovering a nuclear mechanism for GSDMC, the research identifies new therapeutic strategies to target aggressive PDAC phenotypes and improve immunotherapy responses.

• DMG-PEG2000-NH2: Optimizing LNP and Liposomal Drug Delivery

  2026-07-16

  DMG-PEG2000-NH2 stands out as a versatile NH2-PEG derivative for high-efficiency amide bond formation, ideal for constructing advanced liposomal and LNP drug delivery systems. This guide details best-practice workflows, troubleshooting strategies, and the translational impact of functionalized PEG linkers in biomedical research.

• Syringin Sensitizes RCC to Sunitinib via EGFR/PI3K/Akt Inhib

  2026-07-16

  This study identifies Syringin, a natural compound from Acanthopanax senticosus, as a novel adjuvant that enhances Sunitinib efficacy in renal cell carcinoma (RCC) by targeting the EGFR/PI3K/Akt pathway. The findings suggest a promising strategy to overcome drug resistance in advanced RCC and highlight the mechanistic integration of natural products into targeted cancer therapy.

• Tubastatin A Suppresses Myocardial Cell Death After Cardiac

  2026-07-15

  A recent porcine model study demonstrates that Tubastatin A, a selective HDAC6 inhibitor, reduces myocardial injury after cardiac arrest by inhibiting both pyroptosis and necroptosis. These findings reveal a mechanistic link between HDAC6 inhibition and cardioprotection, supporting translational research into cell death modulation in ischemia-reperfusion injury.

• Losmapimod (GW856553X): Redefining p38 MAPK Inhibition in Va

  2026-07-15

  Discover how Losmapimod (GW856553X) advances inflammation signaling modulation and vascular function improvement through a unique dual-action mechanism. This article delivers new insights for experimental design, referencing recent structural biology breakthroughs.

• Capsazepine: TRPV1 Ion Channel Antagonist for Pain Research

  2026-07-14

  Capsazepine enables precise dissection of TRPV1-mediated nociception and apoptosis pathways, empowering researchers to model pain and cancer cell responses with robust reproducibility. APExBIO’s high-purity formulation supports advanced protocol customization and troubleshooting for translational pain and oncological research.

16586 records 1/1106 page Next 12345 下5页 Last page